Uchinchi avlod tutqanoqqa qarshi vositalar: farmakodinamikasi, farmakokinetikasi va qo‘llanilishi

Uchinchi avlod tutqanoqqa qarshi vositalar: farmakodinamikasi, farmakokinetikasi va qo‘llanilishi

Автор: Raximboev Suxrob Davlater ko'mirlar, Sanoev Zafar Isomiddinovich

Журнал: Re-health journal.

Статья в выпуске: 3 (23), 2024 года.

Бесплатный доступ

Tahliliy maqolada yangi avlod epilepsiyaga qarshi vositalar: eslikarbazepin, lakosamid, retigabin, perampanel, everolimus, brivarasetam va zonisamidning farmakologik xususiyatliri ko‘rib chiqiladi. Farmakokinetikasi, ta’sir mexanizmlari, dorilar bilan o‘zaro ta’sirlari, qo‘llashga ko‘rsatmalar va nojo‘ya ta’sirlari haqida ma’lumotlar keltiriladi. Ushbu preparatlar avvalgi qo‘llanilgan birinchi va ikkinchi avlod tutqanoqqa qarshi vositalaridan samaraliroq va xavfsiziroq deb tan olingan. Yangi ochilgan epilepsiyaga qarshi vositalarning ko‘pchiligi fokal hurujlarni, shuningdek spesifik epileptik sindromlar (Lennoks-Gasto sindromi, Dreve sindromi) hamda tuberoz sklerozlarni davolashda ishlatiladi. Preparatlarning ta’sir mexanizmi, farmakokinetik xususiyatlari, klinik samaradorligi va nojo‘ya ta’sirlari bemorlarni davolashda individual yondashuvni talab qiladi. To‘g‘ri tanlangan davo sxemasi epileptik hurujlarni nazoratga olish hamda asoratlar rivojlanishini oldini olishga imkon beradi. Epilepsiyaga qarshi vositalarni tayinlashda ularning farmakokinetikasi va farmakodinamikasini hisobga olish lozim.

Еще

Epilepsiyaga qarshi vositalar, tutqanoqqa qarshi vositalar, tarqalgan epilepsiya, fokal epilepsiya, farmakokinetika, eslikarbazepin, lakosamid, retigabin, perampanel, everolimus, brivarasetam, zonisamid

Короткий адрес: https://sciup.org/14130770

IDR: 14130770

Список литературы Uchinchi avlod tutqanoqqa qarshi vositalar: farmakodinamikasi, farmakokinetikasi va qo‘llanilishi

  • Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. Руководство для врачей. 2-е изд. М.: Бином; 2019: 896 с.
  • Devinsky O., Vezzani A., O’Brien T.J., et al. Epilepsy. Nat Rev Dis Primers. 2018; 4: 18024. https://doi.org/10.1038/nrdp.2018.24.
  • Sanoev Z.I., Ismailova D.S., Rakhimboev S.D., Tolibovich T.T., Elmuradov B.J., Abdinazarov I.T., Rashidov S.Z. (2023). Synthesis And Research Anticonvulsant Activity Of Annulated Triazolothiadiazine Derivative In Laboratory Animals. Biomedical & Pharmacology Journal. Vol. 16(4), p. 2457-2467.
  • Janmohamed M., Brodie M.J., Kwan P. Pharmacoresistance – epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020; 168: 107790. https://doi.org/10.1016/j.neuropharm.2019.107790.
  • Nakken K.O., Brodtkorb E. Are new anti-epileptic drugs any better than their predecessors? Tidsskr Nor Laegeforen. 2020;140 (17). https://doi.org/10.4045/tidsskr.20.0657.
  • Trinka E., Ben-Menachem E., Kowacs P.A., et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsy. 2018; 59 (2): 479–91. https://doi.org/10.1111/epi.13993.
  • Sills G.J., Rogawski M.A. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020; 168: 107966. https://doi.org/10.1016/j.neuropharm.2020.107966.
  • Curatolo P., Napolioni V., Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. J Child Neurol. 2010; 25 (7): 873–80. https://doi. org/10.1177/0883073810361789.
  • Rektor I., Krauss G.L., Bar M., et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012; 126 (4): 263–9. https://doi.org/10.1111/ane.12001.
  • Sanoyev Z. I. Psixotrop vositalar [Matn]: oʻquv qoʻllanma / – Toshkent: “Barkamol Fayz Media”, 2022. – 192 b.
  • Chong DJ, Lerman AM (April 2016). "Practice Update: Review of Anticonvulsant Therapy". Current Neurology and Neuroscience Reports. 16 (4): 39. doi:10.1007/s11910-016-0640-y. PMID 26984292. S2CID 9090302
  • Besag FM, Patsalos PN (2016). "Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures". Neuropsychiatric Disease and Treatment. 12: 1215–20. doi:10.2147/NDT.S83842. PMC 4876101. PMID 27274257. S2CID 14176469
  • Patsalos P.N. The сlinical рharmacology рrofile of the new antiepileptic drug perampanel: а novel noncompetitive AMPA receptor аntagonist. Epilepsia. 2015; 56 (1): 12–27. https://doi.org/10.1111/epi.12865.
  • Patsalos P.N. The сlinical рharmacology рrofile of the new antiepileptic drug perampanel: а novel noncompetitive AMPA receptor аntagonist. Epilepsia. 2015; 56 (1): 12–27. https://doi.org/10.1111/epi.12865.
  • Trinka E., Ben-Menachem E., Kowacs P.A., et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsy. 2018; 59 (2):479–91. https://doi.org/10.1111/epi.13993.
  • Parada A., Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int. 2002; 40 (5): 435–40. https://doi.org/10.1016/S0197-0186(01)00101-2.
  • Singh R.P., Asconapé J.J. A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy. J Cent Nerv Syst Dis. 2011; 3: 179–87. https://doi.org/10.4137/JCNSD.S4888.
  • Mäkinen J., Rainesalo S., Peltola J. Transition from oxcarbazepine to eslicarbazepine acetate: a single center study. Brain Behav. 2017; 7 (3): e00634. https://doi.org/10.1002/brb3.634.
  • Ben-Menachem E., Gabay A.A., Hufnagel A., et al. Eslicarbazepine acetate as an adjunct therapy in adult patients with partial epilepsy. Epilepsy Res. 2010; 89 (2–3): 278–85. https://doi.org/10.1016/j. eplepsyres.2010.01.014.
  • Luzhczky J.J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009; 61 (2): 197–216. https://doi.org/10.1016/s1734-1140(09)70024-6.
  • Ortiz de la Rosa J.S., Ladino L.D., Rodríguez L.D., et al. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory epileptic status: a systematic review. Seizure. 2018; 56: 34–40. https://doi.org/10.1016/j.seizure.2018.01.014.
  • Rogawski M.A., Tofighi A., White H.S., et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015; 110: 189–205. https://doi.org/10.1016/j. eplepsyres.2014.11.021.
  • Rosenfeld V., Fountain N.B., Kaubrys G., et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav. 2014; 41: 164–70. https://doi.org/10.1016/j.yebeh.2014.09.074.
  • Harris J.A., Murphy J.A. Lacosamide and еpilepsy. CNS Neurosci. Ther. 2011; 17 (6): 678–82. https://doi.org/10.1111/j.1755-5949.2010.00198.x.
  • Walleigh D.J., Legido A., Valencia I. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. Pediatr Neurol. 2013; 49 (5): 368–9. http://doi.org/10.1016/j.pediatrneurol.2013.06.005.
  • Bialer M., Johannessen S.I., Kupferberg H.J., et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61 (1–3): 1–48. http://doi.org/10.1016/j.eplepsyres.2004.07.010.
  • Koltzenburg M., McMahon S.B., Tracey I., Turk D.C. (Eds.) Wall and Melzak's textbook of pain. 6 th ed. Philadelphia, PA: Elsevier/Saunders; 2013: 1153 pp.
  • Li M., Zhou Y., Chen C., et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a metaanalysis. Orphanet J Rare Dis. 2019; 14 (1): 39. http://doi.org/10.1186/ s13023-019-1012-x
  • MacKeigan J.P., Krueger D.A. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015; 17 (12): 1550–9. http://doi.org/10.1093/ neuonc/nov152.
  • French J.A., Lawson J.A., Yapichi Z., et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, doubleblind, placebo-controlled study. Lancet. 2016; 388 (10056): 2153–63. http://doi.org/10.1016/S0140-6736(16)31419-2
  • Franz D.N., Lawson J.A., Yapici Z., et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia. 2018; 59 (6): 1188–97. http://doi.org/10.1111/epi.14085.
  • Liu E., Dilley D., McDonough B., et al. Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. Pediatr Drugs. 2019; 21 (4): 291–301. http://doi.org/10.1007/s40272-019-00332-y.
  • Klitgaard H., Matagne A., Nicolas J.M., et al. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016; 57 (4): 538–48. http://doi.org/10.1111/epi.13340.
  • Strzelczyk A., Klein K.M., Willems L.M., et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016; 9 (5): 637–45. http://doi.org/10.1586/17512433.2016.1156529.
  • Dredge D.C. (Ed.) Handbook of pediatric epilepsy education. Springer; 2022: 447 pp.
  • Rolan P., Sargentini-Maier M.L., Pigeolet E., Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile ofbrivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008; 66 (1): 71–5. http://doi.org/10.1111/j.1365-2125.2008.03158.x
  • Kwan S.Y., Chuang Y.C., Huang C.W., et al. Zonisamide: review of recent clinical evidence for treatment of epilepsy. CNS Neurosci Ther. 2015; 21 (9): 683–91. http://doi.org/10.1111/cns.12418.
  • Cornes S.B., Griffn Jr. E.A., Lowenstein D.H. Pharmacology of abnormal electrical neurotransmission in the central nervous system. In: Golan D.E., Armstrong E.J., Armstrong A.W. Principles of pharmacology: the pathophysiologic basis of drug therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017: 249–64.
  • Misty D.M., Metcalf C.S., Wilcox K.S. Pharmacotherapy of the epilepsies. In: Brunton L.L., Hilal-Dandan R., Knollmann B.C. (Eds.) Goodman and Gilman’s: the pharmacological basis of therapeutic. 13th ed. McGraw-Hill; 2018.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp